JP2010535830A - デュシェンヌ型筋ジストロフィーの治療用化合物の製造 - Google Patents

デュシェンヌ型筋ジストロフィーの治療用化合物の製造 Download PDF

Info

Publication number
JP2010535830A
JP2010535830A JP2010520499A JP2010520499A JP2010535830A JP 2010535830 A JP2010535830 A JP 2010535830A JP 2010520499 A JP2010520499 A JP 2010520499A JP 2010520499 A JP2010520499 A JP 2010520499A JP 2010535830 A JP2010535830 A JP 2010535830A
Authority
JP
Japan
Prior art keywords
formula
compound
solvent
production method
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010520499A
Other languages
English (en)
Japanese (ja)
Inventor
チャルレス ウエイモウトフ‐ウイルソン アレクアンデル
ミチャエル ウインネ グラハム
クラルクソン ロベルト
バンウエルル レナテ
パウル ウレン ステプヘン
デ モオル オリビエル
Original Assignee
ビオマリン アイジーエー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビオマリン アイジーエー リミテッド filed Critical ビオマリン アイジーエー リミテッド
Publication of JP2010535830A publication Critical patent/JP2010535830A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2010520499A 2007-08-15 2008-08-14 デュシェンヌ型筋ジストロフィーの治療用化合物の製造 Pending JP2010535830A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0715937.9A GB0715937D0 (en) 2007-08-15 2007-08-15 Method of treatment og duchenne muscular dystrophy
PCT/EP2008/006719 WO2009021749A2 (en) 2007-08-15 2008-08-14 Preparation of a compound for the treatment of duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
JP2010535830A true JP2010535830A (ja) 2010-11-25

Family

ID=38566447

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010520499A Pending JP2010535830A (ja) 2007-08-15 2008-08-14 デュシェンヌ型筋ジストロフィーの治療用化合物の製造
JP2010520498A Pending JP2010535829A (ja) 2007-08-15 2008-08-14 デュシェンヌ型筋ジストロフィーの治療用の化合物の多形体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010520498A Pending JP2010535829A (ja) 2007-08-15 2008-08-14 デュシェンヌ型筋ジストロフィーの治療用の化合物の多形体

Country Status (17)

Country Link
US (2) US8138351B2 (OSRAM)
EP (2) EP2188270A2 (OSRAM)
JP (2) JP2010535830A (OSRAM)
KR (1) KR20100075777A (OSRAM)
CN (2) CN101896475A (OSRAM)
AR (1) AR068810A1 (OSRAM)
AU (2) AU2008286324A1 (OSRAM)
BR (2) BRPI0811315A2 (OSRAM)
CA (2) CA2685590A1 (OSRAM)
CL (1) CL2008002391A1 (OSRAM)
GB (1) GB0715937D0 (OSRAM)
IL (1) IL201908A0 (OSRAM)
MX (2) MX2009011916A (OSRAM)
PE (1) PE20090604A1 (OSRAM)
RU (1) RU2009141831A (OSRAM)
TW (1) TW200911767A (OSRAM)
WO (2) WO2009021749A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017175842A1 (ja) * 2016-04-07 2017-10-12 国立大学法人京都大学 スプライシングの改変に関する化合物及び医薬組成物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101426093B1 (ko) * 2006-02-10 2014-08-01 서미트 코포레이션 피엘씨 뒤시엔느 근이영양증의 치료
GB201208178D0 (en) 2012-05-10 2012-06-20 Summit Corp Plc Pharmaceutical composition for the treatment of duchenne muscular dystrophy
GB201412010D0 (en) 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia
MX2018012018A (es) * 2016-03-30 2019-07-04 Summit Oxford Ltd Composicion para el tratamiento de la distrofía muscular de duchenne.
KR102019048B1 (ko) 2017-02-06 2019-09-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 근육긴장저하 치료제 스크리닝 방법
KR101886788B1 (ko) 2017-02-07 2018-08-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 뒤시엔느 골격근 위축증 치료제 스크리닝 방법
WO2018236879A1 (en) 2017-06-19 2018-12-27 University Of Maryland, Baltimore Microtubule polymerization inhibitor prodrugs and methods of using the same

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993659A (en) * 1971-08-10 1976-11-23 Ciba-Geigy Corporation Bis-benzoxazolyl-naphthalenes as optical brighteners
CH617809GA3 (OSRAM) * 1975-10-10 1980-06-30
US4110246A (en) * 1976-05-13 1978-08-29 Hoechst Aktiengesellschaft Mixture of benzoxazole derivatives
DE3027479A1 (de) * 1980-07-19 1982-03-04 Hoechst Ag, 6000 Frankfurt Mischungen von optischen aufhellern und deren verwendung
JPS615071A (ja) * 1984-06-15 1986-01-10 Fuji Photo Film Co Ltd ベンゾオキサゾ−ル誘導体
DE3617451A1 (de) * 1986-05-23 1987-11-26 Hoechst Ag Sulfonat- oder sulfonamidgruppen-haltige bis-benzoxazolylnaphthaline, verfahren zu deren herstellung und deren verwendung
DE3819051A1 (de) * 1988-06-04 1989-12-07 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial
ES2092080T3 (es) * 1991-08-08 1996-11-16 Ciba Geigy Ag Colorantes, procedimiento para su obtencion y su utilizacion.
ES2157268T5 (es) * 1994-02-24 2004-12-01 SYMRISE GMBH & CO KG Preparados cosmeticos y dermatologicos que contienen acidos fenilen-1,4-bisbencimidazolsulfonicos.
US6004719A (en) * 1994-04-25 1999-12-21 Polaroid Corporation Imaging medium and process for producing an image
WO1996000745A2 (en) * 1994-06-30 1996-01-11 Minnesota Mining And Manufacturing Company Cure-indicating molding and coating composition
DE69530488T2 (de) * 1994-06-30 2004-04-01 Minnesota Mining And Mfg. Co., St. Paul Zahnabdruckmaterial, das einen farbstoff zur sichtbarmachung der härtung enthält
US5567843A (en) * 1995-03-20 1996-10-22 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid)azoles and 2-aminoaryl aminobenz(ox, thi, imid)azoles
US6222044B1 (en) * 1995-03-20 2001-04-24 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid) azoles and 2-aminoaryl aminobenz (ox, thi, imid) azoles
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
US5645948A (en) * 1996-08-20 1997-07-08 Eastman Kodak Company Blue organic electroluminescent devices
US6110638A (en) * 1996-11-27 2000-08-29 Polaroid Corporation Process and composition for generation of acid
US5914213A (en) * 1996-11-27 1999-06-22 Polaroid Corporation Process and composition for generation of acid
US6177572B1 (en) * 1997-08-20 2001-01-23 Sepracor, Inc. Solid and liquid-phase synthesis of benzoxazoles and benzothiazoles and their use
US6312822B1 (en) * 1998-05-28 2001-11-06 Eastman Chem Co Dispersion aids for optical brighteners in polyolefins
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US6436558B1 (en) * 1998-08-07 2002-08-20 Fuji Photo Film Co., Ltd. Organic electroluminescence element
FR2789582B1 (fr) * 1999-02-12 2001-05-04 Oreal Compositions photoprotectrices contenant un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle
FR2789581B1 (fr) * 1999-02-12 2001-05-04 Oreal Compositions photoprotectrices contenant un derive de benzotriazole, un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle
US6541423B1 (en) * 1999-05-07 2003-04-01 Basf Aktiengesellschaft 4-(3′,4′-heterocyclyl benzoyl) pyrazoles as herbicidal agents
CA2373137A1 (en) * 1999-05-07 2000-11-16 Basf Aktiengesellschaft Benzohetero cyclylcyclo hexenones and their use as herbicides
FR2794645B1 (fr) * 1999-06-08 2001-08-10 Oreal Compositions photoprotectrices contenant un compose hydrocarbone bis-hydroxyphenylbenzotriazole et un compose a groupements benzoazolyle ou benzodiazolyle
EP1215203B1 (en) * 1999-09-24 2005-02-16 Ono Pharmaceutical Co., Ltd. Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient
US6565987B2 (en) * 1999-11-12 2003-05-20 Eastman Chemical Company Non-exuding optically brightened polyolefin blends
US20050026811A1 (en) * 2003-05-20 2005-02-03 Mjalli Adnan M. M. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
US6716413B1 (en) * 2000-10-16 2004-04-06 Mallinckrodt, Inc. Indole compounds as tissue-specific exogenous optical agents
KR100825183B1 (ko) * 2000-11-30 2008-04-24 캐논 가부시끼가이샤 발광 소자 및 표시 장치
US20050261298A1 (en) * 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
DK1482931T3 (da) * 2002-03-05 2011-12-19 Transtech Pharma Inc Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE
WO2004035522A1 (ja) * 2002-08-30 2004-04-29 Bf Research Institute, Inc. プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤
CA2523808A1 (en) * 2003-05-16 2004-12-23 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
EP1670787B1 (en) * 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokine inhibitors
DE602004021120D1 (de) * 2003-09-22 2009-06-25 Agfa Graphics Nv Photopolymerisierbare zusammensetzung.
US7097888B2 (en) * 2003-12-15 2006-08-29 Eastman Kodak Company Aligned liquid crystal layer containing azolium salts and process for increasing the tilt
US7592373B2 (en) * 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
US20070185176A1 (en) * 2004-02-06 2007-08-09 Insight Bioharmaceuticals Ltd. Heparanase inhibitors and uses thereof
MY144903A (en) * 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
WO2006019270A1 (en) * 2004-08-19 2006-02-23 Lg Chem. Ltd. Organic light-emitting device comprising buffer layer and method for fabricating the same
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
BRPI0608581A2 (pt) * 2005-03-14 2010-01-19 Transtech Pharma Inc derivados de benzazol, composiÇÕes e mÉtodos de uso como inibidores de b-secretase
JP2007086165A (ja) * 2005-09-20 2007-04-05 Fujifilm Corp 感光性組成物、これを用いた平版印刷版原版及び画像記録方法
EP1960078B1 (en) * 2005-12-02 2014-03-12 Sachem, Inc. Anion-exchange displacement chromatography process
KR101213485B1 (ko) * 2006-01-27 2012-12-18 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
KR101213486B1 (ko) * 2006-02-02 2012-12-20 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
KR101426093B1 (ko) * 2006-02-10 2014-08-01 서미트 코포레이션 피엘씨 뒤시엔느 근이영양증의 치료
KR101325062B1 (ko) * 2006-05-19 2013-11-05 삼성디스플레이 주식회사 발광 이종 핵 구리-이리듐 착체 및 이를 이용한 유기 전계발광 소자

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017175842A1 (ja) * 2016-04-07 2017-10-12 国立大学法人京都大学 スプライシングの改変に関する化合物及び医薬組成物

Also Published As

Publication number Publication date
WO2009021749A8 (en) 2009-09-11
MX2009011967A (es) 2009-11-19
WO2009021748A3 (en) 2009-04-02
BRPI0811548A2 (pt) 2014-11-18
PE20090604A1 (es) 2009-05-16
IL201908A0 (en) 2010-06-16
GB0715937D0 (en) 2007-09-26
CA2685939A1 (en) 2009-02-19
US20090048314A1 (en) 2009-02-19
EP2176246A2 (en) 2010-04-21
CN101896475A (zh) 2010-11-24
CL2008002391A1 (es) 2009-05-22
US8138351B2 (en) 2012-03-20
AU2008286325A1 (en) 2009-02-19
AU2008286324A1 (en) 2009-02-19
CN101679323A (zh) 2010-03-24
CA2685590A1 (en) 2009-02-19
TW200911767A (en) 2009-03-16
RU2009141831A (ru) 2011-05-20
KR20100075777A (ko) 2010-07-05
EP2188270A2 (en) 2010-05-26
WO2009021749A3 (en) 2009-04-02
MX2009011916A (es) 2009-11-18
AR068810A1 (es) 2009-12-09
JP2010535829A (ja) 2010-11-25
WO2009021749A2 (en) 2009-02-19
US20100267961A1 (en) 2010-10-21
WO2009021748A2 (en) 2009-02-19
BRPI0811315A2 (pt) 2015-01-27

Similar Documents

Publication Publication Date Title
US8138351B2 (en) Treatment of duchenne muscular dystrophy
US20120149741A1 (en) Treatment of duchenne muscular dystrophy
Huang et al. A robust TDP-43 knock-in mouse model of ALS
JP6152149B2 (ja) 筋萎縮を阻害するための方法
EP2170396B1 (en) Drug combinations for the treatment of duchenne muscular dystrophy
JP4018884B2 (ja) 脊柱筋萎縮症の治療
WO2008029168A2 (en) Treatment of duchenne muscular dystrophy
US20100048660A1 (en) Treatment of duchenne muscular dystrophy
Syeda et al. Design, synthesis, and in vitro and in vivo evaluation of ouabain analogues as potent and selective Na, K-ATPase α4 isoform inhibitors for male contraception
EP4046657A1 (en) Application of tpk as a target in alzheimer's disease
Suzuki et al. The carboxy-terminus of p63 links cell cycle control and the proliferative potential of epidermal progenitor cells
Chen et al. Cloning and expression of P450c17-I (17α-hydroxylase/17, 20-lyase) in brain and ovary during gonad development in Cynoglossus semilaevis
Banks et al. Loss of symmetric cell division of apical neural progenitors drives DENND5A-related developmental and epileptic encephalopathy
Losby et al. The Estrogen Receptor-Related Orphan Receptors Regulate Autophagy through TFEB
CA3176384A1 (en) Method of treating ship1-mediated diseases using pelorol derivatives
Jiang et al. Expression profile of Chchd10 gene during testicular development
Costigan Investigating the Role of Mitochondrial Metabolism in Human Kidney Development and Maldevelopment
Zhang et al. Ablation of Tmem65 Causes Lethal Mitochondrial Encephalomyopathy in Mouse
Berchowitz et al. The Retrotransposon-Derived Capsid Genes PNMA1 and PNMA4 Maintain Reproductive Capacity
CN121226343A (zh) 3-喹喔啉基咪唑啉硫酮类衍生物、合成方法和应用
Das et al. Autosomal Dominant Polycystic Kidney Disease: At a Glance
CN120607578A (zh) 17β-HSD1抑制剂化合物、药物组合物及其应用
Ho Understanding the Moonlighting Functions of Glycerol Kinase
Bennett The role of RNA helicases in neuromuscular development and diseases
HK1238578A1 (en) Methods of inhibiting muscle atrophy